ChemicalBook > CAS DataBase List > Febuxostat

Febuxostat

Product Name
Febuxostat
CAS No.
144060-53-7
Chemical Name
Febuxostat
Synonyms
FBX;Uloric;Febuxostat Impurity;2-(3-cyano-4-isobutoxyphenyl);TMX 67;CS-1598;Tei-6720;NSC63871;Febrista;Adenuric
CBNumber
CB4841564
Molecular Formula
C16H16N2O3S
Formula Weight
316.37
MOL File
144060-53-7.mol
More
Less

Febuxostat Property

Melting point:
238-239°(dec.)
Boiling point:
536.6±60.0 °C(Predicted)
Density 
1.31±0.1 g/cm3(Predicted)
storage temp. 
2-8°C
solubility 
DMSO (Slightly), Methanol (Slightly)
pka
2.48±0.10(Predicted)
form 
powder
color 
White to Off-White
Merck 
14,3948
InChI
InChI=1S/C16H16N2O3S/c1-9(2)8-21-13-5-4-11(6-12(13)7-17)15-18-10(3)14(22-15)16(19)20/h4-6,9H,8H2,1-3H3,(H,19,20)
InChIKey
BQSJTQLCZDPROO-UHFFFAOYSA-N
SMILES
S1C(C(O)=O)=C(C)N=C1C1=CC=C(OCC(C)C)C(C#N)=C1
CAS DataBase Reference
144060-53-7(CAS DataBase Reference)
More
Less

Safety

RTECS 
XJ3675310
HS Code 
2934.10.2000
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P330Rinse mouth.

P501Dispose of contents/container to..…

More
Less

N-Bromosuccinimide Price

Sigma-Aldrich
Product number
SML1285
Product name
Febuxostat
Purity
98.5-102.0% (HPLC)
Packaging
1G
Price
$202
Updated
2023/06/20
TCI Chemical
Product number
F0847
Product name
Febuxostat
Purity
>97.0%(HPLC)(T)
Packaging
1g
Price
$98
Updated
2024/03/01
TCI Chemical
Product number
F0847
Product name
Febuxostat
Purity
>97.0%(HPLC)(T)
Packaging
5g
Price
$316
Updated
2024/03/01
Cayman Chemical
Product number
14127
Product name
Febuxostat
Purity
≥98%
Packaging
5mg
Price
$57
Updated
2024/03/01
Cayman Chemical
Product number
14127
Product name
Febuxostat
Purity
≥98%
Packaging
10mg
Price
$107
Updated
2024/03/01
More
Less

Febuxostat Chemical Properties,Usage,Production

Description

Febuxostat, a selective xanthine oxidase inhibitor, was launched for the chronic management of hyperuricemia in patients with gout. Hyperuricemia is defined as a serum uric acid concentration exceeding the limit of solubility. It predisposes affected persons to gout, a disease characterized by the formation of crystals of monosodium urate or uric acid from supersaturated fluids in joints and other tissues. Crystal deposition is asymptomatic, but it is revealed by bouts of joint inflammation. If left untreated, further crystals accumulate in joints and can form deposits known as tophi. A major aim in gout management is the long-term reduction of serum uric acid concentrations below saturation levels, as this results in crystal dissolution and eventual disappearance.
Febuxostat is a nonpurine derivative with higher potency and selectivity than allopurinol for inhibiting xanthine oxidase. It completely inhibits human xanthine oxidase activity in the lung cancer cell line A549, whereas the activities of other enzymes involved in purine or pyrimidine metabolism (e.g., purine nucleoside phosphorylase, adenosine deaminase, and pyrimidine nucleoside phosphorylase) are affected by<4%.

Chemical Properties

Crystalline Solid

Physical properties

Febuxostat has low solubility. It is almost insoluble in acidic conditions, slightly soluble in neutral conditions, and slightly more soluble in alkaline conditions. It is not suitable for making injections, but it can be taken orally because of its high oil-water partition coefficient and strong ability to cross cell membranes.

Originator

Teijin (Japan)

Uses

Febuxostat is a new generation xanthine oxidase inhibitor developed by Tejin Co. (Japan,) used clinically for for long-term treatment of hyperuicemia (gout,) a new and highly effective non-purine selective inhibitor of xanthine oxidase. 40-120 mg/day febuxostat was proven effective in lowering serum urate levels when administered to manage hyperuricemia in patients with gout. It is not recommended for gout patients without hyperuricemia.

Preparation

Febuxostat can be synthesized in a multistep sequence from 2,4-dicyanophenol, starting with the alkylation of the phenolic hydroxyl group with isobutyl bromide and potassium carbonate, followed by treatment with thioacetamide in hot dimethyl formamide to yield 3-cyano-4-isobutoxythiobenzamide. Cyclization of the thioamide group with 2-chloroacetoacetic acid ethyl ester in refluxing ethanol affords 2-(3-cyano-4-isoutoxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester, which is hydrolyzed with sodium hydroxide to produce febuxostat.

Definition

ChEBI: Febuxostat is a 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout. It has a role as an EC 1.17.3.2 (xanthine oxidase) inhibitor. It is an aromatic ether, a nitrile and a 1,3-thiazolemonocarboxylic acid.

brand name

Uloric, Adenuric

General Description

Febuxostat is a potent, non-purine compound, which inhibits the expression of cytokines/chemokines. It has also been reported to inhibit LPS-induced TNF-α, VCAM-1, MMP9 and MCP-1 expression.

Biological Activity

Febuxostat is an antihyperuricemic nonpurine inhibitor of both the oxidized and reduced forms of xanthine oxidase. It inhibits bovine milk xanthine oxidase as well as mouse and rat liver xanthine oxidase/xanthine dehydrogenase (IC50s = 1.4, 1.8, and 2.2 nM, respectively). It is 10-30 times more potent than the hypoxanthine analog allopurinol (; Kis = 0.7 nM and 0.7 μM, respectively). Febuxostat decreases the serum level of urate in a potassium oxonate rat model of hyperuricemia (ED50 = 1.5 mg/kg). It reduces hepatic macrovesicular steatosis in mice fed a high-fat diet containing trans fatty acids when administered at a dose of 1 mg/kg per day. Febuxostat (0.75 mg/kg) also increases CNS expression of glutamate oxaloacetate transaminase 2 (GOT2) and improves neurological symptoms in a mouse model of secondary progressive experimental autoimmune encephalomyelitis (EAE). Formulations containing febuxostat have been used in the treatment of symptomatic hyperuricemia in patients with gout.

Biochem/physiol Actions

Febuxostat is a potent non-purine xanithine oxidase inhibitor. Febuxostat is used in urate lowering therapies (ULTs) for the treatment of gout.

Clinical Use

Fabuxostat was discovered by Teijin Pharmaceuticals and licensed to TAP Pharmaceuticals (which is currently part of Takeda Pharmaceuticals) and was approved in the U.S. for the treatment of hyperuricemia in patients with gout. It is a once-daily non-purine based agent with potent inhibitory activity against xanthine oxidase. The safety profile of the drug also does not require dose adjustment for patients with mild to moderate renal or hepatic impairment. Febuxostat is the first new agent cleared for this indication in 40 years.

Side effects

The incidence of adverse events such as dizziness, diarrhea, headache, and nausea with febuxostat was similar to allopurinol. Febuxostat is contraindicated in patients being treated with the xanthine oxidase substrates such as azathioprine, mercaptopurine, and theophylline.

Synthesis

There are a number of routes available to prepare this agent as discussed in recent publications. The synthesis shown in Scheme 10 is a short and concise route and does not require the use of toxic reagents. Thus the commercially available and easily prepared 4-hydroxythiobenzamide (52) was reacted with ethyl bromoacetoacetate (53) in refluxing ethanol to provide the thiazole ester 54 in ??60% yield after crystallization. The phenolic ester 54 was then treated with hexamethylenetetramine (HMTA) in polyphosphoric acid at 80 ??C to provide the crude aldehyde 55 (74% conversion by HPLC). Reaction of phenol 55 and isobutyl bromide (56) in the presence of potassium carbonate with catalytic potassium iodide in DMF gave isobutyl ether 57 (64%, two steps). This ether was then converted in one pot to nitrile 58 in 93% by reacting the aldehyde with hydroxylamine hydrochloride and sodium formate in refluxing formic acid. Saponification of the ester 58 with aqueous sodium hydroxide provided fabuxostat (X).

Drug interactions

Potentially hazardous interactions with other drugs
Azathioprine: avoid concomitant use, increased risk of neutropenia.
Cytotoxics: avoid concomitant use with mercaptopurine.
Theophylline: use with caution

Metabolism

Extensively metabolised by conjugation via the uridine diphosphate glucuronosyltransferase (UDPGT) enzyme system, and by oxidation via the cytochrome P450 isoenzyme system to form active metabolites. About 49% of a dose is excreted via the urine, and 45% via the faeces (12% as unchanged drug)

storage

Store at RT

Mode of action

Xanthine oxidase is the main enzyme promoting uric acid production. It works by non-competitively blocking the molybdenum pterin center, which is the active site of xanthine oxidase. Through highly selective inhibition of oxidized and reduced xanthine oxidase, Febuxostat can reduce the synthesis of uric acid, decreasing its concentration and effectively treating gout. Through liver metabolism, Xanthine oxidase does not rely on renal excretion, so patients with moderate to severe liver and kidney dysfunction do not need to reduce dosages. Febuxostat is a non-purine XOR inhibitor, so it is very safe.

Febuxostat Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

Febuxostat Suppliers

Shandong Mingfeng Pharmaceutical and Technology Co. Ltd
Tel
-1345456643 15315114555
Fax
QQ:1345456643
Email
1345456643@qq.com
Country
China
ProdList
224
Advantage
58
Beijing Mediking Biopharm Co., Ltd
Tel
010-81769521,89753524,81760121 15901403431
Fax
+86-10-81769652
Email
sales01@mediking.cn
Country
China
ProdList
704
Advantage
68
Enki Biopharmaceuticals(Shanghai) Limited
Tel
021-57680965 13916707528
Fax
(21) 5768 0922
Email
yusu@enkibiopharma.com
Country
China
ProdList
44
Advantage
55
Cangzhou Weizhidamei Pharmaceutical Co., Ltd.
Tel
13426038769 13426038769
Fax
0317-5486999
Email
askmryu@163.com
Country
China
ProdList
60
Advantage
58
Jinan Yuantai Pharmaceutical Co.,Ltd
Tel
0531-69959492 18560053868
Fax
0531-88603458
Email
85349064@qq.com
Country
China
ProdList
150
Advantage
58
Beijing Lianben Pharm-Chemicals Tech. Co.,Ltd
Tel
010-83386559 18810831598
Fax
010-83386758
Email
sales@lianben.com
Country
China
ProdList
93
Advantage
58
Shan Dong FengJin Pharmaceutical Co.,Ltd.
Tel
15898960030
Email
tanxiaohui@fengjin-pharma.com
Country
China
ProdList
21
Advantage
58
Ruikangkexin(Hubei)Biotechnology Co., Ltd
Tel
18062078401
Email
290553188@qq.com
Country
China
ProdList
131
Advantage
58
Shanghai Boyle Chemical Co., Ltd.
Tel
Fax
86-21-57758967
Email
sales@boylechem.com
Country
China
ProdList
2922
Advantage
55
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Fax
86-10-82849933
Email
jkinfo@jkchemical.com
Country
China
ProdList
96815
Advantage
76
More
Less

View Lastest Price from Febuxostat manufacturers

Hebei Zhuanglai Chemical Trading Co Ltd
Product
Febuxostat 144060-53-7
Price
US $150.00/kg
Min. Order
1kg
Purity
99%
Supply Ability
500kg
Release date
2024-11-28
Sinoway Industrial co., ltd.
Product
Febuxostat 144060-53-7
Price
US $0.00/Kg/Bag
Min. Order
2Kg/Bag
Purity
99% up, High Density
Supply Ability
20 tons
Release date
2022-08-08
Jinan Jianfeng Chemical Co., Ltd
Product
Febuxostat 144060-53-7
Price
US $0.00/kg
Min. Order
1kg
Purity
99%min
Supply Ability
20ton
Release date
2024-08-09

144060-53-7, FebuxostatRelated Search:


  • Febuxostat (Uloric)
  • FBX
  • Uloric
  • Febuxostat (TEI-6720)
  • Febuxostat Tablets
  • FEBUXOSTAT API
  • Febuxostat (This product is unavailable in the U.S.)
  • Febuxostat Tabletshehe
  • Febuxostat 2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid
  • Febuxostat, >=99%
  • Febuxostat Impurity
  • CS-1598
  • TEI 6720 - Febuxostat
  • 2-(3-cyano-4-isobutoxyphenyl)
  • Febuxostat IMP
  • Tei-6720
  • 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid
  • 2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid
  • 2-(3-Cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic Acid
  • 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazolecarboxylic Acid
  • TMX 67
  • FEBUXOSTAT
  • Febuxosta
  • Febuxostat Impurity V
  • Febuxostat(ThisproductisunavailableintheU.S.)&gt
  • 5-Thiazolecarboxylic acid, 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-
  • Febuxostat A
  • Fubuxostat
  • 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-thiazole-5-carboxylicaci
  • Febuxostat USP/EP/BP
  • Febuxostat Working std
  • Febuxostat (A/C crystal)
  • FebuxostatQ: What is Febuxostat Q: What is the CAS Number of Febuxostat Q: What is the storage condition of Febuxostat Q: What are the applications of Febuxostat
  • NSC 63871
  • NSC63871
  • NSC-63871
  • The cloth sutent
  • Febrista
  • Fesotan *
  • Febuxostat( China GMP )
  • 2-(3-Cyano-4-isobutoxyphenyl)-4-methylthiazol-5-carboxylic acid
  • Febuxostat CRS
  • Febuxostat 2-[3-Cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5- carboxylic acid
  • Febuxostat Form-A, C & G
  • Adenuric
  • Febuxostat Reference Standard
  • 144060-53-7
  • Heterocycles
  • Inhibitors
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • eterocycles
  • TRILIPIX
  • Other APIs
  • Febuxostat
  • API
  • zjh
  • 144060-53-7